2Kurokawa H, arteaga CL. ErbB (HER) receptors can ab- rogate antiestrogen action in human breast cancer by multi- ple signaling mechanisms [ J ]. Clin Cancer Res, 2003,9 (1 Pt2) :511S.
401iveira VM,Piato S, Silva MA. Correlation of cyclooxyge- nase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium[J]. Breast Cancer Res Treat, 2006,95(3) :235 -241.
5Zhang XH, Huang DP, Guo GL, et al. Co-expression of VEGF-C and COX-2 and its association with lymphangio- genesis in human breast cancer[ J]. BMC Cancer,2008, 13(8) :4- 11.
6NLP Barnes, F Warnberg, G Farnie, et al. Cyclooxygen- ase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer [ J ]. British Journal of Cancer, 2007,96 (4) : 575 - 582.
7Ristimaki A, Sivula A, Lundin J, et al. Prognostic signifi- cance of elevated cyclooxygenase-2 expression in breast cancer [ J ]. Cancer Res, 2002,62 ( 3 ) : 632 - 635.
8Wang SC, Lien HC, Xia W, et al. Binding at and transacti- vation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2 [ J ]. Cancer ce11,2004,6 ( 3 ) : 251.
9Winters ZE, Leek RD, Bradburn M J, et al. Cytoplasmic p21 (WAF1/CIP1) expression in correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis [ J ]. Breast cancer Res,2003,5 (6) : 242.
10Rosse T, 01ivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome [ J ]. Na- ture, 1998,391 (6666) :496 - 499.
